博客

血友病

Hemlibra: A Promising Medication for Hemophilia A Patients

Girl with hemophilia receiving bandage on arm

If you have hemophilia A, your doctor might suggest Hemlibra as a treatment option. Approved by the FDA on November 16, 2017, this medicine is used to prevent or reduce bleeding episodes in people with hemophilia A. Hemlibra is seen as a promising alternative to the usual treatments for this condition. In this article, we will discuss Hemlibra, its side effects, dosing information, and much more.

与专家讨论共付额援助

安排咨询

What Is Hemlibra?

Hemlibra (emicizumab-kxwh) is a medication made by Genentech, a subsidiary of the Roche corporation. This medication is used for preventing or reducing bleeding episodes in people with hemophilia A, whether they have factor VIII inhibitors or not. It was first approved by the FDA on November 16, 2017, for hemophilia A patients with factor VIII inhibitors [1]. Later, on October 4, 2018, the approval was extended for patients with hemophilia A without factor VIII inhibitors [2].

People with hemophilia A don’t have enough of a protein called factor VIII in their bodies.

This protein plays a very crucial role in the blood clotting process. Therefore, when someone with hemophilia A gets a cut or injury, their blood doesn’t clot properly. This can lead to longer bleeding, internal bleeding, and more problems.

Before the FDA approved Hemlibra, factor VIII replacement therapy was the primary treatment for hemophilia A. This therapy involved injecting external factor VIII proteins to compensate for the deficiency in hemophilia A patients. However, a common problem with this therapy is that, over time, some people develop inhibitors. Inhibitors are antibodies that attack factor VIII, making the treatment ineffective. Hemlibra offers a solution to this issue. It can prevent bleeding in people with hemophilia A, whether they have inhibitors or not. 

What Is Hemlibra Used To Treat?

Hemlibra is a breakthrough medication that is primarily used to treat hemophilia A. Hemophilia A is a rare genetic disorder that affects blood clotting due to a deficiency in clotting factor VIII. 

Hemlibra is prescribed to be taken regularly. It prevents or reduces bleeding episodes in patients of all ages, including newborns, with hemophilia A [3]. This medication is effective for both adults and children with this condition, whether they have factor VIII inhibitors or not. 

How Does Hemlibra Work?

Hemophilia A is a bleeding disorder caused by a missing clotting factor called factor VIII, which is a protein that helps in blood clotting. When you have an insufficient amount of factor VIII, your blood struggles to form clots when you have an injury. 

Hemlibra is an antibody that mimics factor VIII, the missing protein in hemophilia A.

Normally, factor VIII links factor IX and factor X to aid in blood clotting. However, in hemophilia A, this link is missing. Hemlibra fills this gap by bringing factor IX and factor X together, helping clot formation. This action reduces the danger of bleeding episodes, providing relief to people who have hemophilia A.

The usual treatment for hemophilia A is replacing factor VIII. However, some people may develop inhibitors over time, which can make this treatment ineffective. However, Hemlibra works uniquely. Rather than directly replacing factor VIII, Hemlibra performs the same function as factor VIII by joining other blood proteins. This means it remains effective, even if inhibitors are present. 

副作用

Like all medications, Hemlibra can also cause side effects. In rare cases, it can cause severe side effects. 

常见副作用

Woman with joint pain as a side effect of Hemlibra


The following are some common side effects:

  • 头痛
  • Joint Pain
  • Reactions at the injection site, including redness, warmth, itching, or tenderness

These side effects usually go away on their own after a short time. But, if they worsen or do not go away, consult your doctor or pharmacist.

严重的副作用

Severe side effects from Hemlibra are rare, but they can occur. Contact your doctor right away if you encounter any severe side effects, which include:

  • Blood clots and injury to small blood vessels that cause harm to the kidney, brain, and other organs
  • Blood clots that may form in blood vessels in your arms, legs, lungs, or head
  • Stomach, chest, and back pain
  • Confusion and weakness
  • Swelling, pain, or redness
  • Eye pain or trouble seeing
  • Shortness of breath, coughing up blood

The above list of Hemlibra side effects is not exhaustive. If you encounter any other side effects that are not mentioned above, please consult your doctor. 

获得经济援助

(877) 778-0318

剂量信息

Hemlibra is administered subcutaneously through injections. The dosing depends on various factors like your weight and treatment history. Hemlibra treatment usually starts with loading doses, followed by maintenance doses. Loading doses rapidly increase the drug’s concentration in your body. They are higher than maintenance doses.

The first four doses are loading doses. They are given at 3 mg/kg of body weight once weekly. After that, each subsequent dose is known as a maintenance dose. They are given as:

  • 1.5 mg/kg of body weight once weekly, or
  • 3 mg/kg of body weight once every 2 weeks, or
  • 6 mg/kg of body weight once every 4 weeks

You have to discontinue the use of bypassing agents the day before starting Hemlibra treatment. If you miss a dose, take it as soon as you remember and then continue with your regular dosing schedule. 

Hemlibra Cost

Hemlibra can be expensive, priced at around $122 per mg [5]. The total cost of treatment varies based on your weight. For example, if you weigh 80 kg, the cost of treatment for the first year would be $411,136. For the following years, it would be $381,841. Please remember that this is a rough estimation. The real cost of treatment varies depending on your insurance plan, region, and pharmacy. 

常见问题解答

Here are some answers to frequently asked questions about Hemlibra:

Is Hemlibra Safe for Use During Pregnancy or Breastfeeding?

Hemlibra was mainly tested in males. There is no information about whether Hemlibra can cause harm to an unborn child or if it is present in breast milk. Hemlibra should only be used during pregnancy or breastfeeding if the benefits outweigh the risks.

Can Hemlibra Be Used in Patients With Liver or Kidney Disease?

If you have mild liver or kidney disease, you can still use Hemlibra without needing any changes to the dosage. Data for use in patients with severe liver or kidney disease is insufficient to provide specific recommendations [6]. Please consult your doctor.

Does Hemlibra Cure Hemophilia A?

Unfortunately, there is currently no cure for hemophilia A. Hemlibra can only prevent or reduce the occurrences of bleeding episodes. It cannot cure the disease. 

参考:

  1. Research, C. F. D. E. A. (2017, November 16). FDA approves emicizumab-kxwh for prevention and reduction of bleeding in patients with hemophilia A with factor VIII inhibitors. U.S. Food And Drug Administration. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-emicizumab-kxwh-prevention-and-reduction-bleeding-patients-hemophilia-factor-viii
  2. Research, C. F. D. E. A. (2018, December 14). FDA approves emicizumab-kxwh for hemophilia A with or without factor VIII inhibitors. U.S. Food And Drug Administration. https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-emicizumab-kxwh-hemophilia-or-without-factor-viii-inhibitors
  3. Highlights of prescribing information … (n.d.). https://www.gene.com/download/pdf/hemlibra_prescribing.pdf 
  4. HEMLIBRA® (emicizumab-kxwh) | Hemophilia A Treatment. (n.d.). Hemlibra. https://www.hemlibra.com/
  5. Canadian Agency for Drugs and Technologies in Health. (n.d.). Table 9, CADTH Cost-Comparison Table for Prophylaxis of bleeding in patients with hemophilia A without factor VIII inhibitors – Pharmacoeconomic Report: Emicizumab (Hemlibra) – NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK570443/table/stpe0651.app1.tab1/
  6. Pr HEMLIBRA®. (n.d.-b). https://assets.roche.com/f/173850/x/e0145f9e2a/hemlibra_pm_e.pdf 
此信息不能替代医疗建议或治疗。在开始任何新的治疗之前,请咨询您的医生或医疗保健提供者,了解您的医疗状况。AmeriPharma® Specialty Care 对所提供的信息或由此做出的任何诊断或治疗不承担任何责任,也不对其内容的可靠性负责。AmeriPharma® Specialty Care 并非运营此处列出的所有网站/组织,也不对其内容的可用性或可靠性负责。这些列表并不暗示或构成 AmeriPharma® Specialty Care 的认可、赞助或推荐。本网页可能包含对品牌处方药的引用,这些处方药是与 AmeriPharma® Specialty Care 无关的制药商的商标或注册商标。
Dr. Mark Alfonso
医学审核人 Mark Alfonso 博士,药学博士,BCMTMS

Mark Alfonso 博士,药学博士,在科罗拉多州普韦布洛出生长大。他于 2010 年在科罗拉多大学安舒茨医学院药学院获得药学学位。他于 2022 年获得药物治疗管理委员会认证。他工作中最有成就感的部分是帮助解答患者的疑问和担忧。他的专业领域是社区药房和药物治疗管理。闲暇时,他喜欢阅读和跑步。

联系我们

使用下方符合 HIPAA 标准的表格申请续药。如果您对药物或用药方法有任何疑问,请访问“联系我们”页面或致电 (877) 778-0318.

HIPAA Compliant

提交即表示您同意 AmeriPharma 的 使用条款, 隐私政策, 和 隐私惯例通知

zh_CNChinese